Drug General Information |
Drug ID |
D0V4RP
|
Former ID |
DNC004908
|
Drug Name |
1-(2-Methoxy-phenyl)-piperazine
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C11H16N2O
|
Canonical SMILES |
COC1=CC=CC=C1N2CCNCC2
|
InChI |
1S/C11H16N2O/c1-14-11-5-3-2-4-10(11)13-8-6-12-7-9-13/h2-5,12H,6-9H2,1H3
|
InChIKey |
VNZLQLYBRIOLFZ-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Alpha-1D adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
5-hydroxytryptamine 1D receptor |
Target Info |
Inhibitor |
[2]
|
Alpha-1A adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
5-hydroxytryptamine 2A receptor |
Target Info |
Inhibitor |
[3]
|
5-hydroxytryptamine 1A receptor |
Target Info |
Inhibitor |
[1]
|
5-hydroxytryptamine 6 receptor |
Target Info |
Inhibitor |
[4]
|
KEGG Pathway
|
Calcium signaling pathway
|
cGMP-PKG signaling pathway
|
Neuroactive ligand-receptor interaction
|
Adrenergic signaling in cardiomyocytes
|
Vascular smooth muscle contraction
|
Salivary secretionhsa04024:cAMP signaling pathway
|
Serotonergic synapsehsa04020:Calcium signaling pathway
|
AMPK signaling pathway
|
Salivary secretionhsa04020:Calcium signaling pathway
|
Gap junction
|
Serotonergic synapse
|
Inflammatory mediator regulation of TRP channelshsa04024:cAMP signaling pathway
|
cAMP signaling pathway
|
NetPath Pathway
|
IL2 Signaling Pathway
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
5HT1 type receptor mediated signaling pathwayP00002:Alpha adrenergic receptor signaling pathwayP04374:5HT2 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
5HT1 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
PathWhiz Pathway
|
Excitatory Neural Signalling Through 5-HTR 6 and Serotonin
|
Reactome
|
Adrenoceptors
|
G alpha (q) signalling events
|
G alpha (12/13) signalling eventsR-HSA-390666:Serotonin receptors
|
G alpha (i) signalling eventsR-HSA-390696:Adrenoceptors
|
G alpha (q) signalling eventsR-HSA-390666:Serotonin receptors
|
G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors
|
G alpha (s) signalling events
|
WikiPathways
|
Monoamine GPCRs
|
Calcium Regulation in the Cardiac Cell
|
GPCRs, Class A Rhodopsin-like
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
GPCR ligand binding
|
GPCR downstream signaling
|
GPCRs, OtherWP722:Serotonin HTR1 Group and FOS Pathway
|
GPCR downstream signalingWP58:Monoamine GPCRs
|
Endothelin Pathways
|
AMPK SignalingWP733:Serotonin Receptor 2 and STAT3 Signaling
|
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
|
SIDS Susceptibility Pathways
|
GPCR downstream signalingWP734:Serotonin Receptor 4/6/7 and NR3C Signaling
|
References |
REF 1 | J Med Chem. 1991 Jun;34(6):1850-4.Pyrimido[5,4-b]indole derivatives. 1. A new class of potent and selective alpha 1 adrenoceptor ligands. |
---|
REF 2 | J Med Chem. 1989 May;32(5):1052-6.Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. |
---|
REF 3 | J Med Chem. 1986 May;29(5):630-4.Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. |
---|
REF 4 | Bioorg Med Chem Lett. 2005 Mar 15;15(6):1707-11.1-(1-Naphthyl)piperazine as a novel template for 5-HT6 serotonin receptor ligands. |